167 related articles for article (PubMed ID: 8605088)
1. Polyethylene glycol modification of a galactosylated streptavidin clearing agent: effects on immunogenicity and clearance of a biotinylated anti-tumour antibody.
Marshall D; Pedley RB; Boden JA; Boden R; Melton RG; Begent RH
Br J Cancer; 1996 Mar; 73(5):565-72. PubMed ID: 8605088
[TBL] [Abstract][Full Text] [Related]
2. Galactosylated streptavidin for improved clearance of biotinylated intact and F(ab')2 fragments of an anti-tumour antibody.
Marshall D; Pedley RB; Melton RG; Boden JA; Boden R; Begent RH
Br J Cancer; 1995 Jan; 71(1):18-24. PubMed ID: 7529526
[TBL] [Abstract][Full Text] [Related]
3. Clearance of circulating radio-antibodies using streptavidin or second antibodies in a xenograft model.
Marshall D; Pedley RB; Boden JA; Boden R; Begent RH
Br J Cancer; 1994 Mar; 69(3):502-7. PubMed ID: 8123481
[TBL] [Abstract][Full Text] [Related]
4. Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Reagent development.
Karacay H; Sharkey RM; Govindan SV; McBride WJ; Goldenberg DM; Hansen HJ; Griffiths GL
Bioconjug Chem; 1997; 8(4):585-94. PubMed ID: 9258459
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the chase effects of avidin, streptavidin, neutravidin, and avidin-ferritin on a radiolabeled biotinylated anti-tumor monoclonal antibody.
Kobayashi H; Sakahara H; Endo K; Hosono M; Yao ZS; Toyama S; Konishi J
Jpn J Cancer Res; 1995 Mar; 86(3):310-4. PubMed ID: 7744702
[TBL] [Abstract][Full Text] [Related]
6. Use of galactosylated-streptavidin as a clearing agent with 111In-labeled, biotinylated antibodies to enhance tumor/non-tumor localization ratios.
Govindan SV; Griffiths GL; Michel RB; Andrews PM; Goldenberg DM; Mattes MJ
Cancer Biother Radiopharm; 2002 Jun; 17(3):307-16. PubMed ID: 12136523
[TBL] [Abstract][Full Text] [Related]
7. Improving tumour targeting and decreasing normal tissue uptake by optimizing the stoichiometry of a two-step biotinylated-antibody/streptavidin-based targeting strategy: studies in a nude mouse xenograft model.
Maraveyas A; Rowlinson-Busza G; Murray S; Epenetos AA
Int J Cancer; 1998 Nov; 78(5):610-7. PubMed ID: 9808531
[TBL] [Abstract][Full Text] [Related]
8. Improved targeting of radiolabeled streptavidin in tumors pretargeted with biotinylated monoclonal antibodies through an avidin chase.
Yao Z; Zhang M; Kobayashi H; Sakahara H; Nakada H; Yamashina I; Konishi J
J Nucl Med; 1995 May; 36(5):837-41. PubMed ID: 7738661
[TBL] [Abstract][Full Text] [Related]
9. The potential for enhanced tumour localisation by poly(ethylene glycol) modification of anti-CEA antibody.
Pedley RB; Boden JA; Boden R; Begent RH; Turner A; Haines AM; King DJ
Br J Cancer; 1994 Dec; 70(6):1126-30. PubMed ID: 7981064
[TBL] [Abstract][Full Text] [Related]
10. Role of biotin-binding affinity in streptavidin-based pretargeted radioimmunotherapy of lymphoma.
Hamblett KJ; Press OW; Meyer DL; Hamlin DK; Axworthy D; Wilbur DS; Stayton PS
Bioconjug Chem; 2005; 16(1):131-8. PubMed ID: 15656584
[TBL] [Abstract][Full Text] [Related]
11. Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Studies in a human colon cancer xenograft model.
Sharkey RM; Karacay H; Griffiths GL; Behr TM; Blumenthal RD; Mattes MJ; Hansen HJ; Goldenberg DM
Bioconjug Chem; 1997; 8(4):595-604. PubMed ID: 9258460
[TBL] [Abstract][Full Text] [Related]
12. Intravenous avidin chase improved localization of radiolabeled streptavidin in intraperitoneal xenograft pretargeted with biotinylated antibody.
Zhang M; Sakahara H; Yao Z; Saga T; Nakamoto Y; Sato N; Nakada H; Yamashina I; Konishi J
Nucl Med Biol; 1997 Jan; 24(1):61-4. PubMed ID: 9080476
[TBL] [Abstract][Full Text] [Related]
13. Clearance of yttrium-90-labelled anti-tumour antibodies with antibodies raised against the 12N4 DOTA macrocycle.
Casey JL; King DJ; Pedley RB; Boden JA; Boden R; Chaplin LC; Dorning M; Begent RH
Br J Cancer; 1998 Nov; 78(10):1307-12. PubMed ID: 9823971
[TBL] [Abstract][Full Text] [Related]
14. Iodine-131 and indium-111 labelled avidin and streptavidin for pre-targetted immunoscintigraphy with biotinylated anti-tumour monoclonal antibody.
Pimm MV; Fells HF; Perkins AC; Baldwin RW
Nucl Med Commun; 1988 Nov; 9(11):931-41. PubMed ID: 3251178
[TBL] [Abstract][Full Text] [Related]
15. Pretargeted radioimmunotherapy with a single-chain antibody/streptavidin construct and radiolabeled DOTA-biotin: strategies for reduction of the renal dose.
Förster GJ; Santos EB; Smith-Jones PM; Zanzonico P; Larson SM
J Nucl Med; 2006 Jan; 47(1):140-9. PubMed ID: 16391198
[TBL] [Abstract][Full Text] [Related]
16. Tumor pretargeting: role of avidin/streptavidin on monoclonal antibody internalization.
Casalini P; Luison E; Ménard S; Colnaghi MI; Paganelli G; Canevari S
J Nucl Med; 1997 Sep; 38(9):1378-81. PubMed ID: 9293791
[TBL] [Abstract][Full Text] [Related]
17. Repeating the avidin "chase" markedly improved the biodistribution of radiolabelled biotinylated antibodies and promoted the excretion of additional background radioactivity.
Kobayashi H; Sakahara H; Endo K; Yao ZS; Toyama S; Konishi J
Eur J Cancer; 1995 Sep; 31A(10):1689-96. PubMed ID: 7488426
[TBL] [Abstract][Full Text] [Related]
18. Enhanced tumour specificity of an anti-carcinoembrionic antigen Fab' fragment by poly(ethylene glycol) (PEG) modification.
Delgado C; Pedley RB; Herraez A; Boden R; Boden JA; Keep PA; Chester KA; Fisher D; Begent RH; Francis GE
Br J Cancer; 1996 Jan; 73(2):175-82. PubMed ID: 8546903
[TBL] [Abstract][Full Text] [Related]
19. Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts.
Subbiah K; Hamlin DK; Pagel JM; Wilbur DS; Meyer DL; Axworthy DB; Mallett RW; Theodore LJ; Stayton PS; Press OW
J Nucl Med; 2003 Mar; 44(3):437-45. PubMed ID: 12621012
[TBL] [Abstract][Full Text] [Related]
20. Intraperitoneal radio-localization of tumors pre-targeted by biotinylated monoclonal antibodies.
Paganelli G; Pervez S; Siccardi AG; Rowlinson G; Deleide G; Chiolerio F; Malcovati M; Scassellati GA; Epenetos AA
Int J Cancer; 1990 Jun; 45(6):1184-9. PubMed ID: 2351490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
